Italia Markets close in 3 hrs 30 mins

Bioventus Inc. (BVS)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
6,78+0,25 (+3,83%)
Alla chiusura: 04:00PM EDT
6,50 -0,28 (-4,13%)
Dopo ore: 04:26PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente6,53
Aperto6,68
Denaro6,74 x 400
Domanda6,80 x 400
Min-Max giorno6,56 - 7,04
Intervallo di 52 settimane2,70 - 7,04
Volume410.311
Media Volume281.928
Capitalizzazione432,751M
Beta (mensile su 5 anni)0,89
Rapporto PE (ttm)N/D
EPS (ttm)-0,33
Prossima data utili06 ago 2024 - 12 ago 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A8,50
  • GlobeNewswire

    Bioventus to Present at the Cantor Global Healthcare Conference

    DURHAM, N.C., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice president and chief financial officer, will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 28, 2023, at 1:50 p.m. ET. A live audio webcast of the fireside chat will be available on the “Investors” section of the Company’s website at www.bioventus.com and will be availabl

  • GlobeNewswire

    Bioventus to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

    DURHAM, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Tony Bihl, interim chief executive officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Wednesday, September 13, 2023, at 8:50 a.m. ET. A live audio webcast of the fireside chat will be available on the “Investors” section of the Company’s website at www.bioventus.com and will be available for replay o

  • GlobeNewswire

    Bioventus Reports Second Quarter Financial Results; Introduces Full Year 2023 Financial Guidance

    DURHAM, N.C., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three and six months ended July 1, 2023. Q2 Financial Summary: Net Sales of $137.1 million, down $3.3 million, or 2.3%, year-over-year as reported (2.3% constant currency*), excluding revenues from divested assets, underlying organic sales decreased $0.5 million, or 0.3% year-over-yearNet Loss from